SCP & Co. Healthcare Acquisition Company
SHAC
NASDAQ Capital Market10.08
USD
+0.02
- -
CIK
0001820160
ISIN
US7840651043
CUSIP
784065104
Return %
Stock
S&P500
1Y
3.46
26.84
3Y
3.99
77.03
5Y
3.99
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Scott N. Feuer
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 2909 West Bay to Bay Boulevard Tampa FL United States of America 33629
- IPO Date
- Mar 15, 2021
- CIK
- 0001820160
- Website
- scpandco.com
- Similar Companies
- Business
- SCP & Co. Healthcare Acquisition Company SCP & CO Healthcare Acquisition Company (SHAC) operates as a blank check company, or special purpose acquisition company (SPAC), focused on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses; it targets healthcare technology or healthcare-related platforms primarily in the United States and other developed countries. The company, incorporated in 2020 and headquartered in Tampa, Florida, generates no significant operations or revenues prior to completing an initial business combination. Core activities center on identifying and pursuing high-growth targets in digital health sectors, leveraging sponsor SCP & CO's expertise in healthcare and technology investments. No current products or services operate, as the entity exists solely to facilitate a de-SPAC transaction; upon success, the combined company would offer the target's healthcare technology solutions, such as digital health platforms or related services. In recent developments, the company liquidated in December 2022 after failing to identify and complete a business combination within its 24-month tenor following its $230 million initial public offering in January 2021; public shares were redeemed, extinguishing holder rights, with no merger, acquisition, or extension approved. No subsequent partnerships, funding rounds, new launches, or reorganizations occurred post-liquidation, reflecting the SPAC's unsuccessful pursuit of a healthcare target amid market dynamics.